PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-2634.20%
Negative EBIT growth while CRVO is at 95.96%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
-468.26%
Negative operating income growth while CRVO is at 72.51%. Joel Greenblatt would press for urgent turnaround measures.
-263.73%
Negative net income growth while CRVO stands at 96.19%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
-197.18%
Negative EPS growth while CRVO is at 0.00%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-197.18%
Negative diluted EPS growth while CRVO is at 0.00%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
22.83%
Share change of 22.83% while CRVO is at zero. Bruce Berkowitz would see if slight buybacks (or dilution) matter in the bigger picture.
22.83%
Diluted share change of 22.83% while CRVO is zero. Bruce Berkowitz might see a minor difference that could widen over time.
No Data
No Data available this quarter, please select a different quarter.
-36.01%
Negative OCF growth while CRVO is at 42.71%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-62.21%
Negative FCF growth while CRVO is at 42.61%. Joel Greenblatt would demand improved cost control or more strategic capex discipline.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-319.11%
Negative 10Y OCF/share CAGR while CRVO stands at 0.00%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
-319.11%
Both show negative mid-term OCF/share growth. Martin Whitman might suspect a challenged environment or large capital demands for both.
52.30%
Positive 3Y OCF/share CAGR while CRVO is negative. John Neff might see a big short-term edge in operational efficiency.
-5305.80%
Negative 10Y net income/share CAGR while CRVO is at 0.00%. Joel Greenblatt sees a major red flag in long-term profit erosion.
-5305.80%
Both exhibit negative net income/share growth over five years. Martin Whitman would suspect a challenging environment for the entire niche.
-47.53%
Negative 3Y CAGR while CRVO is 53.42%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.
-1146.88%
Negative equity/share CAGR over 10 years while CRVO stands at 0.00%. Joel Greenblatt sees a fundamental red flag unless the competitor also struggles.
-1146.88%
Both show negative equity/share growth mid-term. Martin Whitman suspects cyclical or structural challenges for each company.
3.51%
Positive short-term equity growth while CRVO is negative. John Neff sees a strong advantage in near-term net worth buildup.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Firm’s AR is declining while CRVO shows 0.00%. Joel Greenblatt sees stronger working capital efficiency if sales hold up.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
9.29%
BV/share growth of 9.29% while CRVO is zero. Bruce Berkowitz sees if small growth can compound into a strong advantage.
10.32%
Debt shrinking faster vs. CRVO's 317.33%. David Dodd sees a safer balance sheet if it doesn't impair future growth.
No Data
No Data available this quarter, please select a different quarter.
402.37%
We expand SG&A while CRVO cuts. John Neff might see the competitor as more cost-optimized unless we expect big payoffs from the overhead growth.